XKRX
200780
Market cap17mUSD
Jul 10, Last price
3,205.00KRW
1D
0.47%
1Q
-25.64%
Jan 2017
-84.82%
IPO
-72.21%
Name
BCWorldPharm Co Ltd
Chart & Performance
P/E
—
P/S
0.36
EPS
—
Div Yield, %
3.13%
Shrs. gr., 5y
4.71%
Rev. gr., 5y
5.86%
Revenues
75.80b
+1.32%
Net income
-4.90b
L+10.47%
CFO
5.58b
+37.97%
Dividend
Dec 29, 2025100 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical enterprise in South Korea, providing a comprehensive range of medical solutions. Its extensive product portfolio addresses diverse therapeutic areas, including the musculoskeletal system, digestive health, cardiovascular disorders, and central nervous system conditions. The company also supplies adrenocorticosteroids, narcotic analgesics, erectile dysfunction therapies, wellness injections, diuretics, antitussive expectorants, vaginitis treatments, anti-tuberculosis medications, anti-emetics, antiviral and antibiotic drugs, anti-malignant tumor agents, antifungal agents, antihistamines, antidotes, and antipyretic, analgesic, and anti-inflammatory compounds. Established in 1980, the firm maintains its headquarters in Seongnam-si, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||